{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:45:34Z","timestamp":1794642334228,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41401-025-01711-7","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:41:12Z","timestamp":1768556472000},"page":"1191-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PLN-L31A\/I40A for the treatment of inherited heart disease caused by PLN-R14del mutations"],"prefix":"10.1038","volume":"47","author":[{"given":"Zi-yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-jia","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-xiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41569-019-0284-0","volume":"17","author":"AN Rosenbaum","year":"2020","unstructured":"Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: practical implications for heart failure management. Nat Rev Cardiol. 2020;17:286\u201397.","journal-title":"Nat Rev Cardiol"},{"key":"1711_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1001\/jama.2021.24674","volume":"327","author":"GS Huggins","year":"2022","unstructured":"Huggins GS, Kinnamon DD, Haas GJ, Jordan E, Hofmeyer M, Kransdorf E, et al. Prevalence and cumulative risk of familial idiopathic dilated cardiomyopathy. JAMA. 2022;327:454\u201363.","journal-title":"JAMA"},{"key":"1711_CR3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","volume":"402","author":"S Heymans","year":"2023","unstructured":"Heymans S, Lakdawala NK, Tschope C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet. 2023;402:998\u20131011.","journal-title":"Lancet"},{"key":"1711_CR4","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1016\/j.jacc.2021.04.030","volume":"77","author":"A Di Marco","year":"2021","unstructured":"Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, et al. Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2021;77:2890\u2013905.","journal-title":"J Am Coll Cardiol"},{"key":"1711_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.hlc.2019.11.018","volume":"29","author":"S Peters","year":"2020","unstructured":"Peters S, Johnson R, Birch S, Zentner D, Hershberger RE, Fatkin D. Familial dilated cardiomyopathy. Heart Lung Circ. 2020;29:566\u201374.","journal-title":"Heart Lung Circ"},{"key":"1711_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/CIRCRESAHA.113.300282","volume":"113","author":"TJ Cahill","year":"2013","unstructured":"Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013;113:660\u201375.","journal-title":"Circ Res"},{"key":"1711_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","volume":"10","author":"RE Hershberger","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531\u201347.","journal-title":"Nat Rev Cardiol"},{"key":"1711_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025257","volume":"11","author":"Q Yang","year":"2022","unstructured":"Yang Q, Berkman AM, Ezekian JE, Rosamilia M, Rosenfeld JA, Liu P, et al. Determining the likelihood of disease pathogenicity among incidentally identified genetic variants in rare dilated cardiomyopathy-associated genes. J Am Heart Assoc. 2022;11:e025257.","journal-title":"J Am Heart Assoc"},{"key":"1711_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrm1151","volume":"4","author":"DH MacLennan","year":"2003","unstructured":"MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566\u201377.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1711_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.yjmcc.2014.10.005","volume":"77","author":"K Haghighi","year":"2014","unstructured":"Haghighi K, Bidwell P, Kranias EG. Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend. J Mol Cell Cardiol. 2014;77:160\u20137.","journal-title":"J Mol Cell Cardiol"},{"key":"1711_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fphar.2014.00005","volume":"5","author":"A Mattiazzi","year":"2014","unstructured":"Mattiazzi A, Kranias EG. The role of CaMKII regulation of phospholamban activity in heart disease. Front Pharmacol. 2014;5:5.","journal-title":"Front Pharmacol."},{"key":"1711_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.bbrc.2004.07.164","volume":"322","author":"K Haghighi","year":"2004","unstructured":"Haghighi K, Gregory KN, Kranias EG. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun. 2004;322:1214\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"1711_CR13","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1073\/pnas.0510519103","volume":"103","author":"K Haghighi","year":"2006","unstructured":"Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA. 2006;103:1388\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1711_CR14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.recesp.2014.11.017","volume":"68","author":"JM Lopez-Ayala","year":"2015","unstructured":"Lopez-Ayala JM, Boven L, van den Wijngaard A, Penafiel-Verdu P, van Tintelen JP, Gimeno JR. Phospholamban p.arg14del mutation in a Spanish family with arrhythmogenic cardiomyopathy: evidence for a European founder mutation. Rev Esp Cardiol (Engl Ed). 2015;68:346\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"1711_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12471-018-1211-4","volume":"27","author":"IE Hof","year":"2019","unstructured":"Hof IE, van der Heijden JF, Kranias EG, Sanoudou D, de Boer RA, van Tintelen JP, et al. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth Heart J. 2019;27:64\u20139.","journal-title":"Neth Heart J"},{"key":"1711_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jacc.2006.07.016","volume":"48","author":"MM DeWitt","year":"2006","unstructured":"DeWitt MM, MacLeod HM, Soliven B, McNally EM. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1396\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1711_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12471-019-1247-0","volume":"27","author":"CC Cheung","year":"2019","unstructured":"Cheung CC, Healey JS, Hamilton R, Spears D, Gollob MH, Mellor G, et al. Phospholamban cardiomyopathy: a Canadian perspective on a unique population. Neth Heart J. 2019;27:208\u201313.","journal-title":"Neth Heart J"},{"key":"1711_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73359-8","volume":"10","author":"X Jiang","year":"2020","unstructured":"Jiang X, Xu Y, Sun J, Wang L, Guo X, Chen Y. The phenotypic characteristic observed by cardiac magnetic resonance in a PLN-R14del family. Sci Rep. 2020;10:16478.","journal-title":"Sci Rep"},{"key":"1711_CR19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2169\/internalmedicine.8594-21","volume":"61","author":"T Tabata","year":"2022","unstructured":"Tabata T, Kuramoto Y, Ohtani T, Miyawaki H, Miyashita Y, Sera F, et al. Phospholamban p.Arg14del cardiomyopathy: a Japanese Case Series. Intern Med. 2022;61:1987\u201393.","journal-title":"Intern Med."},{"key":"1711_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA van der Zwaag","year":"2012","unstructured":"van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199\u2013207.","journal-title":"Eur J Heart Fail"},{"key":"1711_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jmb.2011.06.041","volume":"412","author":"LR Masterson","year":"2011","unstructured":"Masterson LR, Yu T, Shi L, Wang Y, Gustavsson M, Mueller MM, et al. cAMP-dependent protein kinase A selects the excited state of the membrane substrate phospholamban. J Mol Biol. 2011;412:155\u201364.","journal-title":"J Mol Biol"},{"key":"1711_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7955","volume":"6","author":"I Karakikes","year":"2015","unstructured":"Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 2015;6:6955.","journal-title":"Nat Commun"},{"key":"1711_CR23","doi-asserted-by":"crossref","unstructured":"Vafiadaki E, Haghighi K, Arvanitis DA, Kranias EG, Sanoudou D. Aberrant PLN-R14del Protein Interactions Intensify SERCA2a inhibition, driving impaired Ca2+ handling and arrhythmogenesis. Int J Mol Sci. 2022; 23.","DOI":"10.3390\/ijms23136947"},{"key":"1711_CR24","doi-asserted-by":"crossref","unstructured":"Qin J, Zhang J, Lin L, Haji-Ghassemi O, Lin Z, Woycechowsky KJ, et al. Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy. Elife. 2022;11:e75346.","DOI":"10.7554\/eLife.75346"},{"key":"1711_CR25","doi-asserted-by":"crossref","unstructured":"Eijgenraam TR, Boogerd CJ, Stege NM, Teixeira VON, Dokter MM, Schmidt LE, et al. Protein aggregation is an early manifestation of phospholamban p.(Arg14del)-related cardiomyopathy: development of PLN-R14del-related cardiomyopathy. Circ Heart Fail. 2021;14: e008532.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008532"},{"key":"1711_CR26","doi-asserted-by":"crossref","unstructured":"Eijgenraam TR, Boukens BJ, Boogerd CJ, Schouten EM, van de Kolk CWA, Stege NM, et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci Rep. 2020;10:9819.","DOI":"10.1038\/s41598-020-66656-9"},{"key":"1711_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1161\/CIRCULATIONAHA.120.049844","volume":"144","author":"DAM Feyen","year":"2021","unstructured":"Feyen DAM, Perea-Gil I, Maas RGC, Harakalova M, Gavidia AA, Ataam JA, et al. Unfolded protein response as a compensatory mechanism and potential therapeutic target in PLN R14del cardiomyopathy. Circulation. 2021;144:382\u201392.","journal-title":"Circulation."},{"key":"1711_CR28","doi-asserted-by":"crossref","unstructured":"Cuello F, Knaust AE, Saleem U, Loos M, Raabe J, Mosqueira D, et al. Impairment of the ER\/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. Embo Mol Med. 2021; 13.","DOI":"10.15252\/emmm.202013074"},{"key":"1711_CR29","doi-asserted-by":"crossref","unstructured":"Stege NM, de Boer RA, Makarewich CA, van der Meer P, Sillj\u00e9 HHW. Reassessing the mechanisms of PLN-R14del cardiomyopathy: from calcium dysregulation to S\/ER malformation. JACC Basic Transl Sci. 2024;9:1041-52.","DOI":"10.1016\/j.jacbts.2024.02.017"},{"key":"1711_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11897-022-00558-x","volume":"19","author":"FE Deiman","year":"2022","unstructured":"Deiman FE, Bomer N, van der Meer P, Grote Beverborg N. Review: precision medicine approaches for genetic cardiomyopathy: targeting phospholamban R14del. Curr Heart Fail Rep. 2022;19:170\u20139.","journal-title":"Curr Heart Fail Rep"},{"key":"1711_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27461-8","volume":"12","author":"SM Kamel","year":"2021","unstructured":"Kamel SM, van Opbergen CJM, Koopman CD, Verkerk AO, Boukens BJD, de Jonge B, et al. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy. Nat Commun. 2021;12:7151.","journal-title":"Nat Commun"},{"key":"1711_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/CIRCRESAHA.123.323304","volume":"133","author":"NM Stege","year":"2023","unstructured":"Stege NM, Eijgenraam TR, Oliveira Nunes Teixeira V, Feringa AM, Schouten EM, Kuster DWD, et al. DWORF extends life span in a PLN-R14del cardiomyopathy mouse model by reducing abnormal sarcoplasmic reticulum clusters. Circ Res. 2023;133:1006\u201321.","journal-title":"Circ Res."},{"key":"1711_CR33","doi-asserted-by":"crossref","unstructured":"Eijgenraam TR, Stege NM, Oliveira Nunes Teixeira V, de Brouwer R, Schouten EM, Grote Beverborg N, et al. Antisense therapy attenuates phospholamban p.(Arg14del) cardiomyopathy in mice and reverses protein aggregation. Int J Mol Sci. 2022;23:2427.","DOI":"10.3390\/ijms23052427"},{"key":"1711_CR34","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1074\/jbc.272.24.15061","volume":"272","author":"Y Kimura","year":"1997","unstructured":"Kimura Y, Kurzydlowski K, Tada M, MacLennan DH. Phospholamban inhibitory function is activated by depolymerization. J Biol Chem. 1997;272:15061\u20134.","journal-title":"J Biol Chem"},{"key":"1711_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbrc.2012.02.125","volume":"420","author":"SJ Gruber","year":"2012","unstructured":"Gruber SJ, Haydon S, Thomas DD. Phospholamban mutants compete with wild type for SERCA binding in living cells. Biochem Biophys Res Commun. 2012;420:236\u201340.","journal-title":"Biochem Biophys Res Commun"},{"key":"1711_CR36","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1021\/bi047878d","volume":"44","author":"CA Trieber","year":"2005","unstructured":"Trieber CA, Douglas JL, Afara M, Young HS. The effects of mutation on the regulatory properties of phospholamban in co-reconstituted membranes. Biochemistry. 2005;44:3289\u201397.","journal-title":"Biochemistry"},{"key":"1711_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yjmcc.2019.11.147","volume":"138","author":"DR Stroik","year":"2020","unstructured":"Stroik DR, Ceholski DK, Bidwell PA, Mleczko J, Thanel PF, Kamdar F, et al. Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs. J Mol Cell Cardiol. 2020;138:59\u201365.","journal-title":"J Mol Cell Cardiol"},{"key":"1711_CR38","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184:4919\u201338.e22.","journal-title":"Cell"},{"key":"1711_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jala.2011.09.002","volume":"16","author":"B Xi","year":"2011","unstructured":"Xi B, Wang T, Li N, Ouyang W, Zhang W, Wu J, et al. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J Lab Autom. 2011;16:415\u201321.","journal-title":"J Lab Autom"},{"key":"1711_CR40","doi-asserted-by":"crossref","unstructured":"Yu Y, Sun S, Wang S, Zhang Q, Li M, Lan F, et al. Liensinine- and neferine-induced cardiotoxicity in primary neonatal rat cardiomyocytes and human-induced pluripotent stem cell-derived cardiomyocytes. Int J Mol Sci. 2016;17:186.","DOI":"10.3390\/ijms17020186"},{"key":"1711_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57481-7","volume":"16","author":"A Greer-Short","year":"2025","unstructured":"Greer-Short A, Greenwood A, Leon EC, Qureshi TN, von Kraut K, Wong J, et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat Commun. 2025;16:2196.","journal-title":"Nat Commun"},{"key":"1711_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade1633","volume":"14","author":"T Nishiyama","year":"2022","unstructured":"Nishiyama T, Zhang Y, Cui M, Li H, Sanchez-Ortiz E, McAnally JR, et al. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci Transl Med. 2022;14:eade1633.","journal-title":"Sci Transl Med"},{"key":"1711_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-024-08463-0","volume":"639","author":"AF Jebran","year":"2025","unstructured":"Jebran AF, Seidler T, Tiburcy M, Daskalaki M, Kutschka I, Fujita B, et al. Engineered heart muscle allografts for heart repair in primates and humans. Nature. 2025;639:503\u201311.","journal-title":"Nature"},{"key":"1711_CR44","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1161\/CIRCULATIONAHA.117.030785","volume":"137","author":"L Gao","year":"2018","unstructured":"Gao L, Gregorich ZR, Zhu W, Mattapally S, Oduk Y, Lou X, et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation. 2018;137:1712\u201330.","journal-title":"Circulation"},{"key":"1711_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13287-024-03690-8","volume":"15","author":"S Miyagawa","year":"2024","unstructured":"Miyagawa S, Kawamura T, Ito E, Takeda M, Iseoka H, Yokoyama J, et al. Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch. Stem Cell Res Ther. 2024;15:73.","journal-title":"Stem Cell Res Ther"},{"key":"1711_CR46","doi-asserted-by":"publisher","first-page":"e106746","DOI":"10.1371\/journal.pone.0106746","volume":"9","author":"E Hughes","year":"2014","unstructured":"Hughes E, Middleton DA. Comparison of the structure and function of phospholamban and the arginine-14 deficient mutant associated with dilated cardiomyopathy. PLoS One. 2014;9:e106746.","journal-title":"PLoS One"},{"key":"1711_CR47","doi-asserted-by":"crossref","unstructured":"Makarewich CA, Munir AZ, Schiattarella GG, Bezprozvannaya S, Raguimova ON, Cho EE, et al. The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy. Elife. 2018:7:e38319.","DOI":"10.7554\/eLife.38319"},{"key":"1711_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1172\/JCI118446","volume":"97","author":"VJ Kadambi","year":"1996","unstructured":"Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW 2nd, Walsh RA, et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996;97:533\u20139.","journal-title":"J Clin Invest"},{"key":"1711_CR49","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","volume":"117","author":"HX Wang","year":"2017","unstructured":"Wang HX, Li M, Lee CM, Chakraborty S, Kim HW, Bao G, et al. CRISPR\/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev. 2017;117:9874\u2013906.","journal-title":"Chem Rev"},{"key":"1711_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123314","volume":"321","author":"B Moyo","year":"2025","unstructured":"Moyo B, Brown LBC, Khondaker II, Bao G. Engineering adeno-associated viral vectors for CRISPR\/Cas based in vivo therapeutic genome editing. Biomaterials. 2025;321:123314.","journal-title":"Biomaterials"},{"key":"1711_CR51","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/nar\/gkaa1251","volume":"49","author":"YW Fu","year":"2021","unstructured":"Fu YW, Dai XY, Wang WT, Yang ZX, Zhao JJ, Zhang JP, et al. Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. Nucleic Acids Res. 2021;49:969\u201385.","journal-title":"Nucleic Acids Res"},{"key":"1711_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.carpath.2017.05.004","volume":"30","author":"WP Te Rijdt","year":"2017","unstructured":"Te Rijdt WP, van der Klooster ZJ, Hoorntje ET, Jongbloed JDH, van der Zwaag PA, Asselbergs FW, et al. Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovasc Pathol. 2017;30:23\u20136.","journal-title":"Cardiovasc Pathol"},{"key":"1711_CR53","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1161\/CIRCRESAHA.117.311080","volume":"120","author":"Y Yoshida","year":"2017","unstructured":"Yoshida Y, Yamanaka S. Induced pluripotent stem cells 10 years later: for cardiac applications. Circ Res. 2017;120:1958\u201368.","journal-title":"Circ Res."},{"key":"1711_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2022.102737","volume":"60","author":"N Mittal","year":"2022","unstructured":"Mittal N, Dave J, Harakalova M, van Tintelen JP, Asselbergs FW, Doevendans PA, et al. Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members. Stem Cell Res. 2022;60:102737.","journal-title":"Stem Cell Res"},{"key":"1711_CR55","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nature22403","volume":"546","author":"H Kilpinen","year":"2017","unstructured":"Kilpinen H, Goncalves A, Leha A, Afzal V, Alasoo K, Ashford S, et al. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature. 2017;546:370\u20135.","journal-title":"Nature"},{"key":"1711_CR56","doi-asserted-by":"crossref","unstructured":"Tang J, Amin MA, Campian JL. Past, present, and future of viral vector vaccine platforms: a comprehensive review. Vaccines (Basel). 2025;13:524.","DOI":"10.3390\/vaccines13050524"},{"key":"1711_CR57","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo A, Fernandez A, Low SH, Francois A, Suarez-Amaran L, Samulski RJ. AAV vectors: The Rubik\u2019s cube of human gene therapy. Mol Ther. 2022;30:3515\u201341.","journal-title":"Mol Ther"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01711-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:03:46Z","timestamp":1777025026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01711-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author Xin Xie is a member of the Editorial Board of the journal Acta Pharmacologica Sinica, but she has not been involved in the peer-review or decision-making process for this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}